Blockade of EP4 by ASP7657 Modulates Myeloid Cell Differentiation In Vivo and Enhances the Antitumor Effect of Radiotherapy

Figure 3

ASP7657 activates T cell-mediated antitumor activity. (a, b) CT26.WT cells were inoculated ( (a) or (b) cells per mouse) into the right flank of BALB/c (a) and nude mice (b). After tumors were established, mice were treated with ASP7657 twice per day. (c) 4T1-ova cells were inoculated ( cells per mouse) into the right mammary fat pad of BALB/c mice. After tumors were established, mice were treated with ASP7657 twice per day and injected with an anti-mCD8 antibody at 0.2 mg/head twice per week (biw). Data show for mice per group. , compared with the vehicle group (Dunnett’s multiple comparison test); ^#, compared with the 10 mg/kg/day group (Student’s -test).

(a)

(b)

(c)